Advanced search
Publication Cover
Pharmacogenomics Volume 10, 2009 - Issue 9
Submit an article Journal homepage
589
Views
0
CrossRef citations to date
0
Altmetric
Review

Sex-Specific Differences in Side Effects of Psychotropic Drugs: Genes or Gender?

Sara Haack1 Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Helmholtzstr. 20, 89081Ulm, Germany Tel.: +49 731 5002 3899; Fax: +49 731 5006 5605; [email protected];2 Carl Carus University Hospital Dresden, Dresden, Germany
,
Angela Seeringer1 Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Helmholtzstr. 20, 89081Ulm, Germany Tel.: +49 731 5002 3899; Fax: +49 731 5006 5605; [email protected]
,
Petra A Thürmann3 Philipp Klee-Institute of Clinical Pharmacology University of Witten/Herdecke HELIOS Klinikum Wuppertal Wuppertal, Germany
,
Thomas Becker1 Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Helmholtzstr. 20, 89081Ulm, Germany Tel.: +49 731 5002 3899; Fax: +49 731 5006 5605; [email protected]
&
Julia Kirchheiner1 Institute of Pharmacology of Natural Products and Clinical Pharmacology, University Ulm, Helmholtzstr. 20, 89081Ulm, Germany Tel.: +49 731 5002 3899; Fax: +49 731 5006 5605; [email protected]
Pages 1511-1526 | Published online: 17 Sep 2009

Bibliography

  • Martin RM , BiswasPN, FreemantleSN, PearceGL, MannRD: Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies.Br. J. Clin. Pharmacol.46 , 505–511 (1998).
  • Rademaker M : Do women have more adverse drug reactions?Am. J. Clin. Dermatol.2 , 349–351 (2001).
  • Anderson GD : Gender differences in pharmacological response.Int. Rev. Neurobiol.83 , 1–10 (2008).
  • Kim JS , NafzigerAN: Is it sex or is it gender?Clin. Pharmacol. Ther.68 , 1–3 (2000).
  • Hutson WR , RoehrkasseRL, WaldA: Influence of gender and menopause on gastric emptying and motility.Gastroenterology96 , 11–17 (1989).
  • Kashuba AD , NafzigerAN: Physiological changes during the menstrual cycle and their effects on the pharmacokinetics and pharmacodynamics of drugs.Clin. Pharmacokinet.34 , 203–218 (1998).
  • Stahl SM : Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.J. Clin. Psychiatry59(Suppl. 4) , 5–14 (1998).
  • Schwartz JB : The influence of sex on pharmacokinetics.Clin. Pharmacokinet.42 , 107–121 (2003).
  • Beierle I , MeibohmB, DerendorfH: Gender differences in pharmacokinetics and pharmacodynamics.Int. J. Clin. Pharmacol. Ther.37 , 529–547 (1999).
  • Prior TI , BakerGB: Interactions between the cytochrome P450 system and the second-generation antipsychotics.J. Psychiatry Neurosci.28 , 99–112 (2003).
  • Gex-Fabry M , Balant-GorgiaAE, BalantLP, RudazS, VeutheyJL, BertschyG: Time course of clinical response to venlafaxine: relevance of plasma level and chirality.Eur. J. Clin. Pharmacol.59 , 883–891 (2004).
  • Gex-Fabry M , RudazS, Balant-GorgiaAE et al.: Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.Eur. J. Clin. Pharmacol.58 , 323–331 (2002).
  • Thurmann PA , HompeschBC: Influence of gender on the pharmacokinetics and pharmacodynamics of drugs.Int. J. Clin. Pharmacol. Ther.36 , 586–590 (1998).
  • Hagg S , SpigsetO, DahlqvistR: Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.Br. J. Clin. Pharmacol.51 , 169–173 (2001).
  • Meibohm B , BeierleI, DerendorfH: How important are gender differences in pharmacokinetics?Clin. Pharmacokinet.41 , 329–342 (2002).
  • Parkinson A , MudraDR, JohnsonC, DwyerA, CarrollKM: The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.Toxicol. Appl. Pharmacol.199 , 193–209 (2004).
  • Tamminga WJ , WemerJ, OosterhuisB et al.: CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.Eur. J. Clin. Pharmacol.55 , 177–184 (1999).
  • Gex-Fabry M , Balant-GorgiaAE, BalantLP, GarroneG: Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.Clin. Pharmacokinet.19 , 241–255 (1990).
  • Weiss U , MarksteinerJ, KemmlerG, SariaA, AichhornW: Effects of age and sex on olanzapine plasma concentrations.J. Clin. Psychopharmacol.25 , 570–574 (2005).
  • Kelly C , McCreadieRG: Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland.Am. J. Psychiatry156 , 1751–1757 (1999).
  • Skogh E , ReisM, DahlML, LundmarkJ, BengtssonF: Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting.Ther. Drug Monit.24 , 518–526 (2002).
  • Haring C , MeiseU, HumpelC, SariaA, FleischhackerWW, HinterhuberH: Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age.Psychopharmacology (Berl.)99(Suppl.) , S38–S40 (1989).
  • Lane HY , ChangYC, ChangWH, LinSK, TsengYT, JannMW: Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics.J. Clin. Psychiatry60 , 36–40 (1999).
  • Rostami-Hodjegan A , AminAM, SpencerEP, LennardMS, TuckerGT, FlanaganRJ: Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients.J. Clin. Psychopharmacol.24 , 70–78 (2004).
  • Hasselstrom J , LinnetK: Quetiapine serum concentrations in psychiatric patients: the influence of comedication.Ther. Drug Monit.26 , 486–491 (2004).
  • Wilner KD , TensfeldtTG, BarisB et al.: Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.Br. J. Clin. Pharmacol.49(Suppl. 1) , S15–S20 (2000).
  • Aichhorn W , WhitworthAB, WeissEM, MarksteinerJ: Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?Drug Saf.29 , 587–598 (2006).
  • Callaghan JT , BergstromRF, PtakLR, BeasleyCM: Olanzapine: pharmacokinetic and pharmacodynamic profile.Clin. Pharmacokinet.37 , 177–193 (1999).
  • Palego L , BiondiL, GiannacciniG et al.: Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: influence of patient-related variables.Prog. Neuropsychopharmacol. Biol. Psychiatry26 , 473–480 (2002).
  • Usall J , ArayaS, OchoaS, BusquetsE, GostA, MarquezM: Gender differences in a sample of schizophrenic outpatients.Compr. Psychiatry42 , 301–305 (2001).
  • Back DJ , OrmeML: Pharmacokinetic drug interactions with oral contraceptives.Clin. Pharmacokinet.18 , 472–484 (1990).
  • Harris RZ , BenetLZ, SchwartzJB: Gender effects in pharmacokinetics and pharmacodynamics.Drugs50 , 222–239 (1995).
  • Pollock BG : Gender differences in psychotropic drug metabolism.Psychopharmacol. Bull.33 , 235–241 (1997).
  • Gross JL , FriedmanR, AzevedoMJ, SilveiroSP, PecisM: Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA.Braz. J. Med. Biol. Res.25 , 129–134 (1992).
  • Muller MJ , RegenbogenB, SachseJ, EichFX, HartterS, HiemkeC: Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.Pharmacopsychiatry39 , 41–46 (2006).
  • Schuetz EG , FuruyaKN, SchuetzJD: Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms.J. Pharmacol. Exp. Ther.275 , 1011–1018 (1995).
  • Rathore SS , WangY, KrumholzHM: Sex-based differences in the effect of digoxin for the treatment of heart failure.N. Engl. J. Med.347 , 1403–1411 (2002).
  • Melkersson KI , HultingAL, RaneAJ: Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.Br. J. Clin. Pharmacol.51 , 317–324 (2001).
  • Arnold LM , StrakowskiSM, SchwiersML et al.: Sex, ethnicity, and antipsychotic medication use in patients with psychosis.Schizophr. Res.66 , 169–175 (2004).
  • Salokangas RK : Gender and the use of neuroleptics in schizophrenia.Schizophr. Res.66 , 41–49 (2004).
  • Naber D , KarowA: Good tolerability equals good results: the patient‘s perspective.Eur. Neuropsychopharmacol.11(Suppl. 4) , S391–S396 (2001).
  • Kasper S : First-episode schizophrenia: the importance of early intervention and subjective tolerability.J. Clin. Psychiatry60(Suppl. 23) , 5–9 (1999).
  • Awad AG , VorugantiLN: New antipsychotics, compliance, quality of life, and subjective tolerability – are patients better off?Can. J. Psychiatry49 , 297–302 (2004).
  • Barbui C , NoseM, BindmanJ et al.: Sex differences in the subjective tolerability of antipsychotic drugs.J. Clin. Psychopharmacol.25 , 521–526 (2005).
  • Hildebrandt MG , SteyerbergEW, StageKB, PasschierJ, Kragh-SoerensenP: Are gender differences important for the clinical effects of antidepressants?Am. J. Psychiatry160 , 1643–1650 (2003).
  • Hamilton JA , HalbreichU: Special aspects of neuropsychiatric illness in women: with a focus on depression.Annu. Rev. Med.44 , 355–364 (1993).
  • Frackiewicz EJ , SramekJJ, CutlerNR: Gender differences in depression and antidepressant pharmacokinetics and adverse events.Ann. Pharmacother.34 , 80–88 (2000).
  • Parsons B , AllisonDB, LoebelA et al.: Weight effects associated with antipsychotics: a comprehensive database analysis.Schizophr. Res.110 , 103–110 (2009).
  • Muller DJ , KennedyJL: Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Pharmacogenomics7 , 863–887 (2006).
  • Bouchard C , PerusseL: Genetic aspects of obesity.Ann. NY Acad. Sci.699 , 26–35 (1993).
  • Rankinen T , ZuberiA, ChagnonYC et al.: The human obesity gene map: the 2005 update.Obesity (Silver Spring)14 , 529–644 (2006).
  • Reynolds GP , HillMJ, KirkSL: The 5-HT2C receptor and antipsychoticinduced weight gain – mechanisms and genetics.J. Psychopharmacol.20 , 15–18 (2006).
  • Reynolds GP , ZhangZ, ZhangX: Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain.Am. J. Psychiatry160 , 677–679 (2003).
  • Gregoor JG , van der Weide J, Mulder H et al.: Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J. Clin. Psychopharmacol.29 , 21–25 (2009).
  • Russell JM , MackellJA: Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications.CNS Drugs15 , 537–551 (2001).
  • Homel P , CaseyD, AllisonDB: Changes in body mass index for individuals with and without schizophrenia, 1987–1996.Schizophr. Res.55 , 277–284 (2002).
  • Covell NH , WeissmanEM, EssockSM: Weight gain with clozapine compared to first generation antipsychotic medications.Schizophr. Bull.30 , 229–240 (2004).
  • Bobes J , RejasJ, Garcia-GarciaM et al.: Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.Schizophr. Res.62 , 77–88 (2003).
  • Frankenburg FR , ZanariniMC, KandoJ, CentorrinoF: Clozapine and body mass change.Biol. Psychiatry43 , 520–524 (1998).
  • Heimberg C , GallacherF, GurRC, GurRE: Diet and gender moderate clozapine-related weight gain.Hum. Psychopharmacol.10 , 367–371 (1995).
  • Bai YM , LinCC, ChenJY, LinCY: Weight gain among patients on clozapine.Psychiatr. Serv.50 , 704–705 (1999).
  • Basson BR , KinonBJ, TaylorCC, SzymanskiKA, GilmoreJA, TollefsonGD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.J. Clin. Psychiatry62 , 231–238 (2001).
  • Hummer M , KemmlerG, KurzM, KurzthalerI, OberbauerH, FleischhackerWW: Weight gain induced by clozapine.Eur. Neuropsychopharmacol.5 , 437–440 (1995).
  • Umbricht DS , PollackS, KaneJM: Clozapine and weight gain.J. Clin. Psychiatry55(Suppl. B) , 157–160 (1994).
  • McEvoy JP , MeyerJM, GoffDC et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.Schizophr. Res.80 , 19–32 (2005).
  • Kato MM , CurrierMB, GomezCM, HallL, Gonzalez-BlancoM: Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia.Prim. Care Companion J. Clin. Psychiatry6 , 74–77 (2004).
  • Boke O , AkerS, SarisoyG, SaricicekEB, SahinAR: Prevalence of metabolic syndrome among inpatients with schizophrenia.Int. J. Psychiatry Med.38 , 103–112 (2008).
  • Saari KM , LindemanSM, ViiloKM et al.: A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study.J. Clin. Psychiatry66 , 559–563 (2005).
  • Srisurapanont M , LikhitsathianS, BoonyanarutheeV, CharnsilpC, JarusuraisinN: Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study.BMC Psychiatry7 , 14 (2007).
  • Akanji AO , OhaeriJU, Al-ShammriSA, FataniaHR: Associations of blood homocysteine concentrations in Arab schizophrenic patients.Clin. Biochem.40 , 1026–1031 (2007).
  • Wang HC , YangYK, ChenPS, LeeIH, YehTL, LuRB: Increased plasma leptin in antipsychotic-naive females with schizophrenia, but not in males.Neuropsychobiology56 , 213–215 (2007).
  • Meyer JM , DavisVG, GoffDC et al.: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.Schizophr. Res.101 , 273–286 (2008).
  • Osser DN , NajarianDM, DufresneRL: Olanzapine increases weight and serum triglyceride levels.J. Clin. Psychiatry60 , 767–770 (1999).
  • Henderson DC , CaglieroE, GrayC et al.: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.Am. J. Psychiatry157 , 975–981 (2000).
  • Henderson DC , CaglieroE, CopelandPM et al.: Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Arch. Gen. Psychiatry62 , 19–28 (2005).
  • Kim SH , IvanovaO, AbbasiFA, LamendolaCA, ReavenGM, GlickID: Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.J. Clin. Psychopharmacol.27 , 365–368 (2007).
  • Meyer JM , DavisVG, McEvoyJP et al.: Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.Schizophr. Res.103 , 104–109 (2008).
  • Gaulin BD , MarkowitzJS, CaleyCF, NesbittLA, DufresneRL: Clozapine-associated elevation in serum triglycerides.Am. J. Psychiatry156 , 1270–1272 (1999).
  • Ostbye T , CurtisLH, MasselinkLE et al.: Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.Pharmacoepidemiol. Drug Saf.14 , 407–415 (2005).
  • Danesh J , LewingtonS: Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies.J. Cardiovasc. Risk5 , 229–232 (1998).
  • Applebaum J , ShimonH, SelaBA, BelmakerRH, LevineJ: Homocysteine levels in newly admitted schizophrenic patients.J. Psychiatr. Res.38 , 413–416 (2004).
  • Wilson PW , D‘AgostinoRB, PariseH, SullivanL, MeigsJB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus.Circulation112 , 3066–3072 (2005).
  • Goff DC , SullivanLM, McEvoyJP et al.: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.Schizophr. Res.80 , 45–53 (2005).
  • Ray WA , ChungCP, MurrayKT, HallK, SteinCM: Atypical antipsychotic drugs and the risk of sudden cardiac death.N. Engl. J. Med.360 , 225–235 (2009).
  • Mulder H , CohenD, SchefferH et al.: HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study.J. Clin. Psychopharmacol.29 , 16–20 (2009).
  • Srivastava V , DeshpandeSN, NimgaonkarVL, LererB, ThelmaB: Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes.Pharmacogenomics9 , 1055–1068 (2008).
  • Yevtushenko OO , CooperSJ, O‘NeillR, DohertyJK, WoodsideJV, ReynoldsGP: Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia.Br. J. Psychiatry192 , 424–428 (2008).
  • Ellingrod VL , Miller del D, Taylor SF, Moline J, Holman T, Kerr J: Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr. Res.98 , 47–54 (2008).
  • Mulder H , FrankeB, van der-Beek van der AA et al.: The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J. Clin. Psychopharmacol.27 , 338–343 (2007).
  • Gunes A , MelkerssonKI, ScordoMG, DahlML: Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.J. Clin. Psychopharmacol.29 , 65–68 (2009).
  • Kelly DL : Treatment considerations in women with schizophrenia.J. Womens Health (Larchmt)15 , 1132–1140 (2006).
  • O‘Keane V , MeaneyAM: Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?J. Clin. Psychopharmacol.25 , 26–31 (2005).
  • Kopecek M , BaresM, SvarcJ, DockeryC, HoracekJ: Hyperprolactinemia after low dose of amisulpride.Neuro. Endocrinol. Lett.25 , 419–422 (2004).
  • Haddad PM , WieckA: Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.Drugs64 , 2291–2314 (2004).
  • Volavka J , CzoborP, CooperTB et al.: Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.J. Clin. Psychiatry65 , 57–61 (2004).
  • Wieck A , HaddadPM: Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.Br. J. Psychiatry182 , 199–204 (2003).
  • Montgomery J , WinterbottomE, JessaniM et al.: Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment.J. Clin. Psychiatry65 , 1491–1498 (2004).
  • Kuruvilla A , PeedicayilJ, SrikrishnaG, KuruvillaK, KanagasabapathyAS: A study of serum prolactin levels in schizophrenia: comparison of males and females.Clin. Exp. Pharmacol. Physiol.19 , 603–606 (1992).
  • Smith S , WheelerMJ, MurrayR, O‘KeaneV: The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.J. Clin. Psychopharmacol.22 , 109–114 (2002).
  • Knegtering R , CasteleinS, BousH et al.: A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning.J. Clin. Psychopharmacol.24 , 56–61 (2004).
  • Knegtering H , van der Moolen AE, Castelein S, Kluiter H, van den Bosch RJ: What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology28(Suppl. 2) , 109–123 (2003).
  • Claus A , BollenJ, De Cuyper H et al.: Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr. Scand.85 , 295–305 (1992).
  • Halbreich U , KinonBJ, GilmoreJA, KahnLS: Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.Psychoneuroendocrinology28(Suppl. 1) , 53–67 (2003).
  • Hummer M , HuberJ: Hyperprolactinaemia and antipsychotic therapy in schizophrenia.Curr. Med. Res. Opin.20 , 189–197 (2004).
  • Ghadirian AM , ChouinardG, AnnableL: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients.J. Nerv. Ment. Dis.170 , 463–467 (1982).
  • Beumont PJ , CorkerCS, FriesenHG et al.: The effects of phenothiazines on endocrine function: II. Effects in men and post-menopausal women.Br. J. Psychiatry124 , 420–430 (1974).
  • Kim YK , KimL, LeeMS: Risperidone and associated amenorrhea: a report of 5 cases.J. Clin. Psychiatry60 , 315–317 (1999).
  • Hankinson SE , WillettWC, MichaudDS et al.: Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women.J. Natl Cancer Inst.91 , 629–634 (1999).
  • Wang PS , WalkerAM, TsuangMT et al.: Dopamine antagonists and the development of breast cancer.Arch. Gen. Psychiatry59 , 1147–1154 (2002).
  • Oksbjerg D alton S, Munk Laursen T, Mellemkjaer L, Johansen C, Mortensen PB: Schizophrenia and the risk for breast cancer. Schizophr. Res.62 , 89–92 (2003).
  • Klibanski A , NeerRM, BeitinsIZ, RidgwayEC, ZervasNT, McArthurJW: Decreased bone density in hyperprolactinemic women.N. Engl. J. Med.303 , 1511–1514 (1980).
  • Abraham G , PaingWW, KaminskiJ, JosephA, KohegyiE, JosiassenRC: Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study.Am. J. Psychiatry160 , 1618–1620 (2003).
  • Becker D , LiverO, MesterR, RapoportM, WeizmanA, WeissM: Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.J. Clin. Psychiatry64 , 761–766 (2003).
  • Meaney AM , SmithS, HowesOD, O‘BrienM, MurrayRM, O‘KeaneV: Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.Br. J. Psychiatry184 , 503–508 (2004).
  • Aizenberg D , ZemishlanyZ, Dorfman-EtrogP, WeizmanA: Sexual dysfunction in male schizophrenic patients.J. Clin. Psychiatry56 , 137–141 (1995).
  • Wirshing DA , PierreJM, MarderSR, SaundersCS, WirshingWC: Sexual side effects of novel antipsychotic medications.Schizophr. Res.56 , 25–30 (2002).
  • Aizenberg D , ModaiI, LandaA, Gil-AdI, WeizmanA: Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine.J. Clin. Psychiatry62 , 541–544 (2001).
  • Macdonald S , HallidayJ, MacET et al.: Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case–control study.Br. J. Psychiatry182 , 50–56 (2003).
  • Meston CM , FrohlichPF: The neurobiology of sexual function.Arch. Gen. Psychiatry57 , 1012–1030 (2000).
  • Teusch L , ScherbaumN, BohmeH, BenderS, Eschmann-MehlG, GastparM: Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts.Pharmacopsychiatry28 , 84–92 (1995).
  • Yap YG , CammJ: Risk of torsades de pointes with non-cardiac drugs. Doctors need to be aware that many drugs can cause qt prolongation.BMJ320 , 1158–1159 (2000).
  • Czekalla J , BeasleyCM Jr, Dellva MA, Berg PH, Grundy S: Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J. Clin. Psychiatry62 , 191–198 (2001).
  • Agelink MW , MajewskiT, WurthmannC et al.: Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine.J. Clin. Psychopharmacol.21 , 8–13 (2001).
  • Litherland S : Drug treatment and schizophrenia in the 1990s.Drugs54 , 794 (1997).
  • Harrigan EP , MiceliJJ, AnzianoR et al.: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.J. Clin. Psychopharmacol.24 , 62–69 (2004).
  • Haverkamp W , BreithardtG, CammAJ et al.: The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.Cardiovasc. Res.47 , 219–233 (2000).
  • Roden DM : Torsade de pointes.Clin. Cardiol.16 , 683–686 (1993).
  • Haverkamp W , MonnigG, Schulze-BahrE, HaverkampF, BreithardtG: Physician-induced torsade de pointes – therapeutic implications.Cardiovasc. Drugs Ther.16 , 101–109 (2002).
  • Bailey MS , CurtisAB: The effects of hormones on arrhythmias in women.Curr. Womens Health Rep.2 , 83–88 (2002).
  • Makkar RR , FrommBS, SteinmanRT, MeissnerMD, LehmannMH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.JAMA270 , 2590–2597 (1993).
  • Larsen JA , KadishAH: Effects of gender on cardiac arrhythmias.J. Cardiovasc. Electrophysiol.9 , 655–664 (1998).
  • Lehmann MH , HardyS, ArchibaldD, QuartB, MacNeilDJ: Sex difference in risk of torsade de pointes with d,l-sotalol.Circulation94 , 2535–2541 (1996).
  • Wolbrette D : Gender differences in the proarrhythmic potential of QT-prolonging drugs.Curr. Womens Health Rep.2 , 105–109 (2002).
  • Kawasaki R , MachadoC, ReinoehlJ et al.: Increased propensity of women to develop torsades de pointes during complete heart block.J. Cardiovasc. Electrophysiol.6 , 1032–1038 (1995).
  • Ebert SN , LiuXK, WoosleyRL: Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence.J. Womens Health7 , 547–557 (1998).
  • Drici MD , ClementN: Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.Drug Saf.24 , 575–585 (2001).
  • Kassotis J , CosteasC, BediAK, TolatA, ReiffelJ: Effects of aging and gender on QT dispersion in an overtly healthy population.Pacing Clin. Electrophysiol.23 , 1121–1126 (2000).
  • Roe CM , OdellKW, HendersonRR: Concomitant use of antipsychotics and drugs that may prolong the QT interval.J. Clin. Psychopharmacol.23 , 197–200 (2003).
  • van Os J , FahyT, JonesP, HarveyI, TooneB, MurrayR: Tardive dyskinesia: who is at risk?Acta Psychiatr. Scand.96 , 206–216 (1997).
  • Casey DE : Tardive dyskinesia and atypical antipsychotic drugs.Schizophr. Res.35(Suppl.) , S61–S66 (1999).
  • Yassa R , JesteDV: Gender differences in tardive dyskinesia: a critical review of the literature.Schizophr. Bull.18 , 701–715 (1992).
  • Seeman P : Brain dopamine receptors in schizophrenia and tardive dyskinesia.Psychopharmacology Suppl.2 , 1–8 (1985).
  • Morgenstern H , GlazerWM: Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.Arch. Gen. Psychiatry50 , 723–733 (1993).
  • van Os J , WalshE, van Horn E, Tattan T, Bale R, Thompson SG: Tardive dyskinesia in psychosis: are women really more at risk? UK700 Group. Acta Psychiatr. Scand.99 , 288–293 (1999).
  • Waddington JL : Sight and insight: brain dopamine receptor occupancy by neuroleptics visualised in living schizophrenic patients by positron emission tomography.Br. J. Psychiatry154 , 433–436 (1989).
  • Seeman P , Chau-WongM, TedescoJ, WongK: Brain receptors for antipsychotic drugs and dopamine: direct binding assays.Proc. Natl Acad. Sci. USA72 , 4376–4380 (1975).
  • Thelma B , SrivastavaV, TiwariAK: Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.Pharmacogenomics9 , 1285–1306 (2008).
  • Arranz MJ , de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry12 , 707–747 (2007).
  • Correll CU , LeuchtS, KaneJM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.Am. J. Psychiatry161 , 414–425 (2004).
  • Correll CU , SchenkEM: Tardive dyskinesia and new antipsychotics.Curr. Opin. Psychiatry21 , 151–156 (2008).
  • Davidson M , HarveyPD, VervarckeJ et al.: A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.Int. J. Geriatr. Psychiatry15 , 506–514 (2000).
  • Casey DE : Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.Schizophr. Res.4 , 109–120 (1991).
  • Grohmann R , KochR, SchmidtLG: Extrapyramidal symptoms in neuroleptic recipients.Agents Actions Suppl.29 , 71–82 (1990).
  • Labelle A , LightM, DunbarF: Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response.Can. J. Psychiatry46 , 534–541 (2001).
  • Kornstein S , SchatzbergAF, ThaseME et al. Gender differences in treatment response to sertaline versus imipramine in chronic depression. Am J. Psychiatry 157(9) , 1445–1452 (2000).
  • Gregorian RS , GoldenKA, BahceA, GoodmanC, KwongWJ, KhanZM: Antidepressant-induced sexual dysfunction.Ann. Pharmacother.36 , 1577–1589 (2002).
  • Montejo AL , LlorcaG, IzquierdoJA, Rico-VillademorosF: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.J. Clin. Psychiatry62(Suppl. 3) , 10–21 (2001).
  • Clayton AH : Female sexual dysfunction related to depression and antidepressant medications.Curr. Womens Health Rep.2 , 182–187 (2002).
  • Clayton AH , PradkoJF, CroftHA et al.: Prevalence of sexual dysfunction among newer antidepressants.J. Clin. Psychiatry63 , 357–366 (2002).
  • Kennedy SH , EisfeldBS, DickensSE, BacchiochiJR, BagbyRM: Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.J. Clin. Psychiatry61 , 276–281 (2000).
  • Piazza LA , MarkowitzJC, KocsisJH et al.: Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study.Am. J. Psychiatry154 , 1757–1759 (1997).
  • Henry C : Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences.J. Psychiatry Neurosci.27 , 104–107 (2002).
  • Frye MA , DenicoffKD, BryanAL et al.: Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients.Am. J. Psychiatry156 , 1909–1914 (1999).
  • Vincent A , BaruchP, VincentP: Early onset of lithium-associated hypothyroidism.J. Psychiatry Neurosci.18 , 74–77 (1993).
  • Bocchetta A , BernardiF, PedditziM et al.: Thyroid abnormalities during lithium treatment.Acta Psychiatr. Scand.83 , 193–198 (1991).
  • Johnston AM , EaglesJM: Lithium-associated clinical hypothyroidism. Prevalence and risk factors.Br. J. Psychiatry175 , 336–339 (1999).
  • Vestergaard P , AmdisenA, SchouM: Clinically significant side effects of lithium treatment. A survey of 237 patients in long-term treatment.Acta Psychiatr. Scand.62 , 193–200 (1980).
  • Vestergaard P , LichtRW, BrodersenA et al.: Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels.Acta Psychiatr. Scand.98 , 310–315 (1998).
  • Teixeira NA , KarniolIG: The influence of age and sex on weight variation in rats treated chronically with lithium chloride.Acta Pharmacol. Toxicol. (Copenh.)51 , 1–5 (1982).
  • Vendsborg PB , BechP, RafaelsenOJ: Lithium treatment and weight gain.Acta Psychiatr. Scand.53 , 139–147 (1976).
  • Volzke E , DooseH: Dipropylacetate (Depakine, Ergenyl) in the treatment of epilepsy.Epilepsia14 , 185–193 (1973).
  • Hassan MN , LaljeeHC, ParsonageMJ: Sodium valproate in the treatment of resistant epilepsy.Acta Neurol. Scand.54 , 209–218 (1976).
  • Covanis A , GuptaAK, JeavonsPM: Sodium valproate: monotherapy and polytherapy.Epilepsia23 , 693–720 (1982).
  • Schmidt D : Adverse effects of valproate.Epilepsia25(Suppl. 1) , S44–S49 (1984).
  • Jallon P , PicardF: Bodyweight gain and anticonvulsants: a comparative review.Drug Saf.24 , 969–978 (2001).
  • El-Khatib F , RauchenzaunerM, LechleitnerM et al.: Valproate, weight gain and carbohydrate craving: a gender study.Seizure16 , 226–232 (2007).
  • Dinesen H , GramL, AndersenT, DamM: Weight gain during treatment with valproate.Acta Neurol. Scand.70 , 65–69 (1984).
  • Bilo L , MeoR: Polycystic ovary syndrome in women using valproate: a review.Gynecol. Endocrinol.24 , 562–570 (2008).
  • Morrell MJ , HayesFJ, SlussPM et al.: Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine.Ann. Neurol.64 , 200–211 (2008).
  • Rasgon NL , AltshulerLL, GudemanD et al.: Medication status and polycystic ovary syndrome in women with bipolar disorder: a preliminary report.J. Clin. Psychiatry61 , 173–178 (2000).
  • Rasgon NL , AltshulerLL, FairbanksL et al.: Reproductive function and risk for PCOS in women treated for bipolar disorder.Bipolar Disord.7 , 246–259 (2005).
  • McIntyre RS , ManciniDA, McCannS, SrinivasanJ, KennedySH: Valproate, bipolar disorder and polycystic ovarian syndrome.Bipolar Disord.5 , 28–35 (2003).
  • O‘Donovan C , KusumakarV, GravesGR, BirdDC: Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder.J. Clin. Psychiatry63 , 322–330 (2002).
  • Tohen M , CastilloJ, BaldessariniRJ, ZarateC Jr, Kando JC: Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am. J. Psychiatry152 , 413–418 (1995).
  • Trannel TJ , AhmedI, GoebertD: Occurrence of thrombocytopenia in psychiatric patients taking valproate.Am. J. Psychiatry158 , 128–130 (2001).
  • Stubner S , GrohmannR, EngelR et al.: Blood dyscrasias induced by psychotropic drugs.Pharmacopsychiatry37(Suppl. 1) , S70–S78 (2004).
  • Tran C , KnowlesSR, LiuBA, ShearNH: Gender differences in adverse drug reactions.J. Clin. Pharmacol.38 , 1003–1009 (1998).
  • Alvestad S , LydersenS, BrodtkorbE: Rash from antiepileptic drugs: influence by gender, age, and learning disability.Epilepsia48 , 1360–1365 (2007).
  • Gau SS , ChaoPF, LinYJ, ChangCJ, GauCS: The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case–control study.J. Clin. Psychopharmacol.28 , 509–517 (2008).
  • Bate A : Sex differences in suspected adverse drug reaction reports: data mining analysis of the four million record WHO database.Gender Med.5 , 300–301 (2008) (Abstract).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.